 | • レポートコード：MRC2-11QY11635 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は糖尿病性末梢神経障害治療のグローバル市場について調査・分析したレポートです。種類別（アンチムノセル、ASP-8477、BNV-222、カプサイシン、CBX-129801、その他）市場規模、用途別（病院、クリニック、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別糖尿病性末梢神経障害治療の競争状況、市場シェア ・世界の糖尿病性末梢神経障害治療市場：種類別市場規模 2015年-2020年（アンチムノセル、ASP-8477、BNV-222、カプサイシン、CBX-129801、その他） ・世界の糖尿病性末梢神経障害治療市場：種類別市場規模予測 2021年-2026年（アンチムノセル、ASP-8477、BNV-222、カプサイシン、CBX-129801、その他） ・世界の糖尿病性末梢神経障害治療市場：用途別市場規模 2015年-2020年（病院、クリニック、その他） ・世界の糖尿病性末梢神経障害治療市場：用途別市場規模予測 2021年-2026年（病院、クリニック、その他） ・北米の糖尿病性末梢神経障害治療市場分析：米国、カナダ ・ヨーロッパの糖尿病性末梢神経障害治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの糖尿病性末梢神経障害治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の糖尿病性末梢神経障害治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの糖尿病性末梢神経障害治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Achelios Therapeutics Inc、Celgene Corp、Commence Bio Inc、Grunenthal GmbH、Immune Pharmaceuticals Inc、KPI Therapeutics Inc、Medifron DBT Co Ltd、Mitsubishi Tanabe Pharma Corp、Novaremed Ltd、Reata Pharmaceuticals Inc、Relief Therapeutics Holding AG、ViroMed Co Ltd ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Diabetic Peripheral Neuropathy Treatment Market
The global Diabetic Peripheral Neuropathy Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Diabetic Peripheral Neuropathy Treatment Scope and Market Size
Diabetic Peripheral Neuropathy Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Diabetic Peripheral Neuropathy Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Achelios Therapeutics Inc
Celgene Corp
Commence Bio Inc
Grunenthal GmbH
Immune Pharmaceuticals Inc
KPI Therapeutics Inc
Medifron DBT Co Ltd
Mitsubishi Tanabe Pharma Corp
Novaremed Ltd
Reata Pharmaceuticals Inc
Relief Therapeutics Holding AG
ViroMed Co Ltd
Market segment by Type, the product can be split into
Antimunocel
ASP-8477
BNV-222
Capsaicin
CBX-129801
Others
Market segment by Application, split into
Hospital
Clinic
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Diabetic Peripheral Neuropathy Treatment Revenue
1.4 Market by Type
1.4.1 Global Diabetic Peripheral Neuropathy Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Antimunocel
1.4.3 ASP-8477
1.4.4 BNV-222
1.4.5 Capsaicin
1.4.6 CBX-129801
1.4.7 Others
1.5 Market by Application
1.5.1 Global Diabetic Peripheral Neuropathy Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Diabetic Peripheral Neuropathy Treatment Market Perspective (2015-2026)
2.2 Global Diabetic Peripheral Neuropathy Treatment Growth Trends by Regions
2.2.1 Diabetic Peripheral Neuropathy Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Diabetic Peripheral Neuropathy Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Diabetic Peripheral Neuropathy Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Diabetic Peripheral Neuropathy Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Diabetic Peripheral Neuropathy Treatment Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Diabetic Peripheral Neuropathy Treatment Players by Market Size
3.1.1 Global Top Diabetic Peripheral Neuropathy Treatment Players by Revenue (2015-2020)
3.1.2 Global Diabetic Peripheral Neuropathy Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Diabetic Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Diabetic Peripheral Neuropathy Treatment Market Concentration Ratio
3.2.1 Global Diabetic Peripheral Neuropathy Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Diabetic Peripheral Neuropathy Treatment Revenue in 2019
3.3 Diabetic Peripheral Neuropathy Treatment Key Players Head office and Area Served
3.4 Key Players Diabetic Peripheral Neuropathy Treatment Product Solution and Service
3.5 Date of Enter into Diabetic Peripheral Neuropathy Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Diabetic Peripheral Neuropathy Treatment Historic Market Size by Type (2015-2020)
4.2 Global Diabetic Peripheral Neuropathy Treatment Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Diabetic Peripheral Neuropathy Treatment Market Size by Application (2015-2020)
5.2 Global Diabetic Peripheral Neuropathy Treatment Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Diabetic Peripheral Neuropathy Treatment Market Size (2015-2020)
6.2 Diabetic Peripheral Neuropathy Treatment Key Players in North America (2019-2020)
6.3 North America Diabetic Peripheral Neuropathy Treatment Market Size by Type (2015-2020)
6.4 North America Diabetic Peripheral Neuropathy Treatment Market Size by Application (2015-2020)
7 Europe
7.1 Europe Diabetic Peripheral Neuropathy Treatment Market Size (2015-2020)
7.2 Diabetic Peripheral Neuropathy Treatment Key Players in Europe (2019-2020)
7.3 Europe Diabetic Peripheral Neuropathy Treatment Market Size by Type (2015-2020)
7.4 Europe Diabetic Peripheral Neuropathy Treatment Market Size by Application (2015-2020)
8 China
8.1 China Diabetic Peripheral Neuropathy Treatment Market Size (2015-2020)
8.2 Diabetic Peripheral Neuropathy Treatment Key Players in China (2019-2020)
8.3 China Diabetic Peripheral Neuropathy Treatment Market Size by Type (2015-2020)
8.4 China Diabetic Peripheral Neuropathy Treatment Market Size by Application (2015-2020)
9 Japan
9.1 Japan Diabetic Peripheral Neuropathy Treatment Market Size (2015-2020)
9.2 Diabetic Peripheral Neuropathy Treatment Key Players in Japan (2019-2020)
9.3 Japan Diabetic Peripheral Neuropathy Treatment Market Size by Type (2015-2020)
9.4 Japan Diabetic Peripheral Neuropathy Treatment Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Diabetic Peripheral Neuropathy Treatment Market Size (2015-2020)
10.2 Diabetic Peripheral Neuropathy Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Diabetic Peripheral Neuropathy Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Diabetic Peripheral Neuropathy Treatment Market Size by Application (2015-2020)
11 India
11.1 India Diabetic Peripheral Neuropathy Treatment Market Size (2015-2020)
11.2 Diabetic Peripheral Neuropathy Treatment Key Players in India (2019-2020)
11.3 India Diabetic Peripheral Neuropathy Treatment Market Size by Type (2015-2020)
11.4 India Diabetic Peripheral Neuropathy Treatment Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Diabetic Peripheral Neuropathy Treatment Market Size (2015-2020)
12.2 Diabetic Peripheral Neuropathy Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Diabetic Peripheral Neuropathy Treatment Market Size by Type (2015-2020)
12.4 Central & South America Diabetic Peripheral Neuropathy Treatment Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Achelios Therapeutics Inc
13.1.1 Achelios Therapeutics Inc Company Details
13.1.2 Achelios Therapeutics Inc Business Overview
13.1.3 Achelios Therapeutics Inc Diabetic Peripheral Neuropathy Treatment Introduction
13.1.4 Achelios Therapeutics Inc Revenue in Diabetic Peripheral Neuropathy Treatment Business (2015-2020))
13.1.5 Achelios Therapeutics Inc Recent Development
13.2 Celgene Corp
13.2.1 Celgene Corp Company Details
13.2.2 Celgene Corp Business Overview
13.2.3 Celgene Corp Diabetic Peripheral Neuropathy Treatment Introduction
13.2.4 Celgene Corp Revenue in Diabetic Peripheral Neuropathy Treatment Business (2015-2020)
13.2.5 Celgene Corp Recent Development
13.3 Commence Bio Inc
13.3.1 Commence Bio Inc Company Details
13.3.2 Commence Bio Inc Business Overview
13.3.3 Commence Bio Inc Diabetic Peripheral Neuropathy Treatment Introduction
13.3.4 Commence Bio Inc Revenue in Diabetic Peripheral Neuropathy Treatment Business (2015-2020)
13.3.5 Commence Bio Inc Recent Development
13.4 Grunenthal GmbH
13.4.1 Grunenthal GmbH Company Details
13.4.2 Grunenthal GmbH Business Overview
13.4.3 Grunenthal GmbH Diabetic Peripheral Neuropathy Treatment Introduction
13.4.4 Grunenthal GmbH Revenue in Diabetic Peripheral Neuropathy Treatment Business (2015-2020)
13.4.5 Grunenthal GmbH Recent Development
13.5 Immune Pharmaceuticals Inc
13.5.1 Immune Pharmaceuticals Inc Company Details
13.5.2 Immune Pharmaceuticals Inc Business Overview
13.5.3 Immune Pharmaceuticals Inc Diabetic Peripheral Neuropathy Treatment Introduction
13.5.4 Immune Pharmaceuticals Inc Revenue in Diabetic Peripheral Neuropathy Treatment Business (2015-2020)
13.5.5 Immune Pharmaceuticals Inc Recent Development
13.6 KPI Therapeutics Inc
13.6.1 KPI Therapeutics Inc Company Details
13.6.2 KPI Therapeutics Inc Business Overview
13.6.3 KPI Therapeutics Inc Diabetic Peripheral Neuropathy Treatment Introduction
13.6.4 KPI Therapeutics Inc Revenue in Diabetic Peripheral Neuropathy Treatment Business (2015-2020)
13.6.5 KPI Therapeutics Inc Recent Development
13.7 Medifron DBT Co Ltd
13.7.1 Medifron DBT Co Ltd Company Details
13.7.2 Medifron DBT Co Ltd Business Overview
13.7.3 Medifron DBT Co Ltd Diabetic Peripheral Neuropathy Treatment Introduction
13.7.4 Medifron DBT Co Ltd Revenue in Diabetic Peripheral Neuropathy Treatment Business (2015-2020)
13.7.5 Medifron DBT Co Ltd Recent Development
13.8 Mitsubishi Tanabe Pharma Corp
13.8.1 Mitsubishi Tanabe Pharma Corp Company Details
13.8.2 Mitsubishi Tanabe Pharma Corp Business Overview
13.8.3 Mitsubishi Tanabe Pharma Corp Diabetic Peripheral Neuropathy Treatment Introduction
13.8.4 Mitsubishi Tanabe Pharma Corp Revenue in Diabetic Peripheral Neuropathy Treatment Business (2015-2020)
13.8.5 Mitsubishi Tanabe Pharma Corp Recent Development
13.9 Novaremed Ltd
13.9.1 Novaremed Ltd Company Details
13.9.2 Novaremed Ltd Business Overview
13.9.3 Novaremed Ltd Diabetic Peripheral Neuropathy Treatment Introduction
13.9.4 Novaremed Ltd Revenue in Diabetic Peripheral Neuropathy Treatment Business (2015-2020)
13.9.5 Novaremed Ltd Recent Development
13.10 Reata Pharmaceuticals Inc
13.10.1 Reata Pharmaceuticals Inc Company Details
13.10.2 Reata Pharmaceuticals Inc Business Overview
13.10.3 Reata Pharmaceuticals Inc Diabetic Peripheral Neuropathy Treatment Introduction
13.10.4 Reata Pharmaceuticals Inc Revenue in Diabetic Peripheral Neuropathy Treatment Business (2015-2020)
13.10.5 Reata Pharmaceuticals Inc Recent Development
13.11 Relief Therapeutics Holding AG
10.11.1 Relief Therapeutics Holding AG Company Details
10.11.2 Relief Therapeutics Holding AG Business Overview
10.11.3 Relief Therapeutics Holding AG Diabetic Peripheral Neuropathy Treatment Introduction
10.11.4 Relief Therapeutics Holding AG Revenue in Diabetic Peripheral Neuropathy Treatment Business (2015-2020)
10.11.5 Relief Therapeutics Holding AG Recent Development
13.12 ViroMed Co Ltd
10.12.1 ViroMed Co Ltd Company Details
10.12.2 ViroMed Co Ltd Business Overview
10.12.3 ViroMed Co Ltd Diabetic Peripheral Neuropathy Treatment Introduction
10.12.4 ViroMed Co Ltd Revenue in Diabetic Peripheral Neuropathy Treatment Business (2015-2020)
10.12.5 ViroMed Co Ltd Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Diabetic Peripheral Neuropathy Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Diabetic Peripheral Neuropathy Treatment Revenue
Table 3. Ranking of Global Top Diabetic Peripheral Neuropathy Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Diabetic Peripheral Neuropathy Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Antimunocel
Table 6. Key Players of ASP-8477
Table 7. Key Players of BNV-222
Table 8. Key Players of Capsaicin
Table 9. Key Players of CBX-129801
Table 10. Key Players of Others
Table 11. Global Diabetic Peripheral Neuropathy Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 12. Global Diabetic Peripheral Neuropathy Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 13. Global Diabetic Peripheral Neuropathy Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 14. Global Diabetic Peripheral Neuropathy Treatment Market Share by Regions (2015-2020)
Table 15. Global Diabetic Peripheral Neuropathy Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 16. Global Diabetic Peripheral Neuropathy Treatment Market Share by Regions (2021-2026)
Table 17. Market Top Trends
Table 18. Key Drivers: Impact Analysis
Table 19. Key Challenges
Table 20. Diabetic Peripheral Neuropathy Treatment Market Growth Strategy
Table 21. Main Points Interviewed from Key Diabetic Peripheral Neuropathy Treatment Players
Table 22. Global Diabetic Peripheral Neuropathy Treatment Revenue by Players (2015-2020) (Million US$)
Table 23. Global Diabetic Peripheral Neuropathy Treatment Market Share by Players (2015-2020)
Table 24. Global Top Diabetic Peripheral Neuropathy Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diabetic Peripheral Neuropathy Treatment as of 2019)
Table 25. Global Diabetic Peripheral Neuropathy Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 26. Key Players Headquarters and Area Served
Table 27. Key Players Diabetic Peripheral Neuropathy Treatment Product Solution and Service
Table 28. Date of Enter into Diabetic Peripheral Neuropathy Treatment Market
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Diabetic Peripheral Neuropathy Treatment Market Size by Type (2015-2020) (Million US$)
Table 31. Global Diabetic Peripheral Neuropathy Treatment Market Size Share by Type (2015-2020)
Table 32. Global Diabetic Peripheral Neuropathy Treatment Revenue Market Share by Type (2021-2026)
Table 33. Global Diabetic Peripheral Neuropathy Treatment Market Size Share by Application (2015-2020)
Table 34. Global Diabetic Peripheral Neuropathy Treatment Market Size by Application (2015-2020) (Million US$)
Table 35. Global Diabetic Peripheral Neuropathy Treatment Market Size Share by Application (2021-2026)
Table 36. North America Key Players Diabetic Peripheral Neuropathy Treatment Revenue (2019-2020) (Million US$)
Table 37. North America Key Players Diabetic Peripheral Neuropathy Treatment Market Share (2019-2020)
Table 38. North America Diabetic Peripheral Neuropathy Treatment Market Size by Type (2015-2020) (Million US$)
Table 39. North America Diabetic Peripheral Neuropathy Treatment Market Share by Type (2015-2020)
Table 40. North America Diabetic Peripheral Neuropathy Treatment Market Size by Application (2015-2020) (Million US$)
Table 41. North America Diabetic Peripheral Neuropathy Treatment Market Share by Application (2015-2020)
Table 42. Europe Key Players Diabetic Peripheral Neuropathy Treatment Revenue (2019-2020) (Million US$)
Table 43. Europe Key Players Diabetic Peripheral Neuropathy Treatment Market Share (2019-2020)
Table 44. Europe Diabetic Peripheral Neuropathy Treatment Market Size by Type (2015-2020) (Million US$)
Table 45. Europe Diabetic Peripheral Neuropathy Treatment Market Share by Type (2015-2020)
Table 46. Europe Diabetic Peripheral Neuropathy Treatment Market Size by Application (2015-2020) (Million US$)
Table 47. Europe Diabetic Peripheral Neuropathy Treatment Market Share by Application (2015-2020)
Table 48. China Key Players Diabetic Peripheral Neuropathy Treatment Revenue (2019-2020) (Million US$)
Table 49. China Key Players Diabetic Peripheral Neuropathy Treatment Market Share (2019-2020)
Table 50. China Diabetic Peripheral Neuropathy Treatment Market Size by Type (2015-2020) (Million US$)
Table 51. China Diabetic Peripheral Neuropathy Treatment Market Share by Type (2015-2020)
Table 52. China Diabetic Peripheral Neuropathy Treatment Market Size by Application (2015-2020) (Million US$)
Table 53. China Diabetic Peripheral Neuropathy Treatment Market Share by Application (2015-2020)
Table 54. Japan Key Players Diabetic Peripheral Neuropathy Treatment Revenue (2019-2020) (Million US$)
Table 55. Japan Key Players Diabetic Peripheral Neuropathy Treatment Market Share (2019-2020)
Table 56. Japan Diabetic Peripheral Neuropathy Treatment Market Size by Type (2015-2020) (Million US$)
Table 57. Japan Diabetic Peripheral Neuropathy Treatment Market Share by Type (2015-2020)
Table 58. Japan Diabetic Peripheral Neuropathy Treatment Market Size by Application (2015-2020) (Million US$)
Table 59. Japan Diabetic Peripheral Neuropathy Treatment Market Share by Application (2015-2020)
Table 60. Southeast Asia Key Players Diabetic Peripheral Neuropathy Treatment Revenue (2019-2020) (Million US$)
Table 61. Southeast Asia Key Players Diabetic Peripheral Neuropathy Treatment Market Share (2019-2020)
Table 62. Southeast Asia Diabetic Peripheral Neuropathy Treatment Market Size by Type (2015-2020) (Million US$)
Table 63. Southeast Asia Diabetic Peripheral Neuropathy Treatment Market Share by Type (2015-2020)
Table 64. Southeast Asia Diabetic Peripheral Neuropathy Treatment Market Size by Application (2015-2020) (Million US$)
Table 65. Southeast Asia Diabetic Peripheral Neuropathy Treatment Market Share by Application (2015-2020)
Table 66. India Key Players Diabetic Peripheral Neuropathy Treatment Revenue (2019-2020) (Million US$)
Table 67. India Key Players Diabetic Peripheral Neuropathy Treatment Market Share (2019-2020)
Table 68. India Diabetic Peripheral Neuropathy Treatment Market Size by Type (2015-2020) (Million US$)
Table 69. India Diabetic Peripheral Neuropathy Treatment Market Share by Type (2015-2020)
Table 70. India Diabetic Peripheral Neuropathy Treatment Market Size by Application (2015-2020) (Million US$)
Table 71. India Diabetic Peripheral Neuropathy Treatment Market Share by Application (2015-2020)
Table 72. Central & South America Key Players Diabetic Peripheral Neuropathy Treatment Revenue (2019-2020) (Million US$)
Table 73. Central & South America Key Players Diabetic Peripheral Neuropathy Treatment Market Share (2019-2020)
Table 74. Central & South America Diabetic Peripheral Neuropathy Treatment Market Size by Type (2015-2020) (Million US$)
Table 75. Central & South America Diabetic Peripheral Neuropathy Treatment Market Share by Type (2015-2020)
Table 76. Central & South America Diabetic Peripheral Neuropathy Treatment Market Size by Application (2015-2020) (Million US$)
Table 77. Central & South America Diabetic Peripheral Neuropathy Treatment Market Share by Application (2015-2020)
Table 78. Achelios Therapeutics Inc Company Details
Table 79. Achelios Therapeutics Inc Business Overview
Table 80. Achelios Therapeutics Inc Product
Table 81. Achelios Therapeutics Inc Revenue in Diabetic Peripheral Neuropathy Treatment Business (2015-2020) (Million US$)
Table 82. Achelios Therapeutics Inc Recent Development
Table 83. Celgene Corp Company Details
Table 84. Celgene Corp Business Overview
Table 85. Celgene Corp Product
Table 86. Celgene Corp Revenue in Diabetic Peripheral Neuropathy Treatment Business (2015-2020) (Million US$)
Table 87. Celgene Corp Recent Development
Table 88. Commence Bio Inc Company Details
Table 89. Commence Bio Inc Business Overview
Table 90. Commence Bio Inc Product
Table 91. Commence Bio Inc Revenue in Diabetic Peripheral Neuropathy Treatment Business (2015-2020) (Million US$)
Table 92. Commence Bio Inc Recent Development
Table 93. Grunenthal GmbH Company Details
Table 94. Grunenthal GmbH Business Overview
Table 95. Grunenthal GmbH Product
Table 96. Grunenthal GmbH Revenue in Diabetic Peripheral Neuropathy Treatment Business (2015-2020) (Million US$)
Table 97. Grunenthal GmbH Recent Development
Table 98. Immune Pharmaceuticals Inc Company Details
Table 99. Immune Pharmaceuticals Inc Business Overview
Table 100. Immune Pharmaceuticals Inc Product
Table 101. Immune Pharmaceuticals Inc Revenue in Diabetic Peripheral Neuropathy Treatment Business (2015-2020) (Million US$)
Table 102. Immune Pharmaceuticals Inc Recent Development
Table 103. KPI Therapeutics Inc Company Details
Table 104. KPI Therapeutics Inc Business Overview
Table 105. KPI Therapeutics Inc Product
Table 106. KPI Therapeutics Inc Revenue in Diabetic Peripheral Neuropathy Treatment Business (2015-2020) (Million US$)
Table 107. KPI Therapeutics Inc Recent Development
Table 108. Medifron DBT Co Ltd Company Details
Table 109. Medifron DBT Co Ltd Business Overview
Table 110. Medifron DBT Co Ltd Product
Table 111. Medifron DBT Co Ltd Revenue in Diabetic Peripheral Neuropathy Treatment Business (2015-2020) (Million US$)
Table 112. Medifron DBT Co Ltd Recent Development
Table 113. Mitsubishi Tanabe Pharma Corp Business Overview
Table 114. Mitsubishi Tanabe Pharma Corp Product
Table 115. Mitsubishi Tanabe Pharma Corp Company Details
Table 116. Mitsubishi Tanabe Pharma Corp Revenue in Diabetic Peripheral Neuropathy Treatment Business (2015-2020) (Million US$)
Table 117. Mitsubishi Tanabe Pharma Corp Recent Development
Table 118. Novaremed Ltd Company Details
Table 119. Novaremed Ltd Business Overview
Table 120. Novaremed Ltd Product
Table 121. Novaremed Ltd Revenue in Diabetic Peripheral Neuropathy Treatment Business (2015-2020) (Million US$)
Table 122. Novaremed Ltd Recent Development
Table 123. Reata Pharmaceuticals Inc Company Details
Table 124. Reata Pharmaceuticals Inc Business Overview
Table 125. Reata Pharmaceuticals Inc Product
Table 126. Reata Pharmaceuticals Inc Revenue in Diabetic Peripheral Neuropathy Treatment Business (2015-2020) (Million US$)
Table 127. Reata Pharmaceuticals Inc Recent Development
Table 128. Relief Therapeutics Holding AG Company Details
Table 129. Relief Therapeutics Holding AG Business Overview
Table 130. Relief Therapeutics Holding AG Product
Table 131. Relief Therapeutics Holding AG Revenue in Diabetic Peripheral Neuropathy Treatment Business (2015-2020) (Million US$)
Table 132. Relief Therapeutics Holding AG Recent Development
Table 133. ViroMed Co Ltd Company Details
Table 134. ViroMed Co Ltd Business Overview
Table 135. ViroMed Co Ltd Product
Table 136. ViroMed Co Ltd Revenue in Diabetic Peripheral Neuropathy Treatment Business (2015-2020) (Million US$)
Table 137. ViroMed Co Ltd Recent Development
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Diabetic Peripheral Neuropathy Treatment Market Share by Type: 2020 VS 2026
Figure 2. Antimunocel Features
Figure 3. ASP-8477 Features
Figure 4. BNV-222 Features
Figure 5. Capsaicin Features
Figure 6. CBX-129801 Features
Figure 7. Others Features
Figure 8. Global Diabetic Peripheral Neuropathy Treatment Market Share by Application: 2020 VS 2026
Figure 9. Hospital Case Studies
Figure 10. Clinic Case Studies
Figure 11. Others Case Studies
Figure 12. Diabetic Peripheral Neuropathy Treatment Report Years Considered
Figure 13. Global Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 14. Global Diabetic Peripheral Neuropathy Treatment Market Share by Regions: 2020 VS 2026
Figure 15. Global Diabetic Peripheral Neuropathy Treatment Market Share by Regions (2021-2026)
Figure 16. Porter's Five Forces Analysis
Figure 17. Global Diabetic Peripheral Neuropathy Treatment Market Share by Players in 2019
Figure 18. Global Top Diabetic Peripheral Neuropathy Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diabetic Peripheral Neuropathy Treatment as of 2019
Figure 19. The Top 10 and 5 Players Market Share by Diabetic Peripheral Neuropathy Treatment Revenue in 2019
Figure 20. North America Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Europe Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. China Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Japan Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Southeast Asia Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. India Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Central & South America Diabetic Peripheral Neuropathy Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Bottom-up and Top-down Approaches for This Report
Figure 28. Data Triangulation
Figure 29. Key Executives Interviewed
末梢神経障害治療の世界市場（～2026年） Peripheral neuropathy is a set of symptoms caused by any damage to the nerves that are away from the brain and spinal cord. Peripheral neuropathy is not a single, homogenous disease, but it is a mix of different clinical presentations, natural histories, and pathology. Market Analysis and Insights: …- 心臓自律神経障害治療の世界市場（～2026年） Cardiac Autonomic Neuropathy treatment market involves aggressively treating cardiovascular risk factors like hypertension. Cardiac autonomicdeficiency of essential fatty acids, increased oxidative stress, autoimmune damage, and formation of advanced glycosylation end products. Other therapies inclu…
- 糖尿病性黄斑浮腫治療の世界市場（～2026年） Diabetic macular edema (DME) is characterized by accumulation of fluid in the macula – a part of retina responsible for vision. Accumulation may cause by leakage of plasma constituents into the surrounding, consequently leading to edema. Increasing prevalence of diabetes in the prime factor driving …
- 糖尿病網膜症（DR）治療の世界市場（～2026年） Diabetic retinopathy (die-uh-BET-ik ret-ih-NOP-uh-thee) is a diabetes complication that affects eyes. It's caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). Market Analysis and Insights: Global Diabetic Retinopathy Treatment Market The global Diabet…
- 糖尿病性神経障害治療薬の世界市場（～2026年） A drug used to treat mental illness caused by diabetes Market Analysis and Insights: Global Diabetic Neurological Disorder Therapeutic Drug Market The global Diabetic Neurological Disorder Therapeutic Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CA…